Dancann Pharma manufactures medical cannabis and develops novel cannabinoid therapeutics for a broad range of diseases.
Dancann Pharma has raised $315K in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2025.
Dancann Pharma's investors include Nordic Growth.
Dancann Pharma is headquartered in Ansager, Denmark.
Dancann Pharma manufactures medical cannabis and develops novel cannabinoid therapeutics for a broad range of diseases.
Dancann Pharma is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dancann Pharma — Funding & Investors." VCBacked, July 9, 2025, https://www.vcbacked.co/company/dancann-pharma. Accessed October 1, 2026.
VCBacked. (2025). Dancann Pharma — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/dancann-pharma
{{cite web |title=Dancann Pharma — Funding & Investors |url=https://www.vcbacked.co/company/dancann-pharma |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated